For instance, PD-L1 expression in the tumor has a sensitivity and specificity ranging from 58% to 85% and 49% to 60%, respectively, depending on the tumor type, applied cut-off or type of anti-PD-1 antibody.31 A similar predictive performance has been reported for TMB.32 The kinase activity profile, reported here, demonstrated a lower predictive performance for response to PD-1 inhibitors in NSCLC compared with melanoma. This evidence concerns the gene CD274 and non-small cell lung carcinoma.